In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

Eli Lilly and Co. (LLY) on Thursday reported second-quarter profit of $5.66 billion. The Indianapolis-based company said it had net income of $6.29 per share.

Trump’s tariffs, including new levies that took effect Thursday, are affecting global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...